Details for Patent: 11,969,544
Which drugs does patent 11,969,544 protect, and when does it expire?
Patent 11,969,544 protects AIRDUO DIGIHALER, AIRDUO RESPICLICK, ARMONAIR DIGIHALER, and ARMONAIR RESPICLICK, and is included in two NDAs.
Protection for AIRDUO DIGIHALER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-five patent family members in sixteen countries.
Summary for Patent: 11,969,544
| Title: | Inhalers and airflow adaptors therefor |
| Abstract: | The present disclosure describes an inhaler for the inhalation of powder medication. The inhaler has a body and at least one reservoir containing powder medication, the body having an air inlet and an outlet for the transmission to a patient of air entering the body through the air inlet and powder medication. The outlet has a total cross-sectional area for flow which is more than 80% of the total cross-sectional area of the air inlet. |
| Inventor(s): | Daniel Buck |
| Assignee: | Norton Waterford Ltd |
| Application Number: | US16/476,390 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 11,969,544
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-004 | Jul 12, 2019 | DISCN | Yes | No | 11,969,544*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-005 | Jul 12, 2019 | DISCN | Yes | No | 11,969,544*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-006 | Jul 12, 2019 | DISCN | Yes | No | 11,969,544*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-001 | Jan 27, 2017 | RX | Yes | Yes | 11,969,544*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-002 | Jan 27, 2017 | RX | Yes | Yes | 11,969,544*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,969,544
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018207234 | ⤷ Start Trial | |||
| Canada | 3049297 | ⤷ Start Trial | |||
| Canada | 3049504 | ⤷ Start Trial | |||
| China | 110177592 | ⤷ Start Trial | |||
| Denmark | 3568181 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
